Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
- Disease/Condition
- Diabetes,Diabetes Mellitus, Type 2
- Drug/Device/Intervention
- Semaglutide
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Novo Nordisk A/S
- Location
- Burgas,Dupnitsa,Lukovit,Madan,Petrich,Ruse,Sliven,Sofia,Vratsa,Brno,Brno,Nachod,Praha 10,Praha 4,Helsinki,Jyväskylä,Kuusamo,Lahti,Oulu,Rauma,Turku,Varkaus,Béziers,Dambach-la-ville,DIJON cedex,LA ROCHE, Bulgaria,Czech,Finland,France,Germany,Hungary,Italy,Poland,Slovenia,Spain,Sweden,United Kingdom
- Phase
- Phase 3
- Start date
- Jun 27, 2017
- End date
- Aug 13, 2018
- Enrollment
- 577 participants
Change in HbA1c
This study is conducted in Europe. The aim of the study is to compare the effect of
 semaglutide subcutaneous (s.c., under the skin) 1.0 mg once-weekly to liraglutide s.c.1.2 mg
 once-daily on blood sugar levels after 30 weeks of treatment in people with type 2 diabetes.
 The study will last approximately 9 months (37 weeks). Each participant will have 7 visits at
 the clinic and 3 phone calls with the study doctor. At the visits, participants will have a
 number of tests, for example: general health checks, blood samples, heart and eye checks etc.
 Participants will also fill in some forms about their health and satisfaction with their
 diabetes treatment.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT03191396
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT03191396 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 577 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.